09:fifty nine AM


Not intended for U.S. and Uk Media


Worldwide section III QUASAR review will assess the efficacy and protection of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study will come right after positive facts from the section III PULSAR trial in neovascular (moist) age-related macular degeneration (nAMD) and stage II/III PHOTON demo in diabetic macular edema (DME) / QUASAR is predicted to enroll close to 800 sufferers in 27 nations around the world / Examine will incorporate to the strong advancement software for aflibercept 8 mg, exploring the likely to attain visual acuity with prolonged procedure intervals in supplemental individual populations